2008 - Review: Long-acting beta-agonists do not increase risk for asthma-related hospitalization in patients taking inhaled corticosteroids

Shafazand, Shirin
March 2009
ACP Journal Club;3/17/2009, Vol. 150 Issue 3, p3
Academic Journal
The article deliberates on the safety of using concomitant therapy with long-acting beta-agonists (LABAs) in asthma patients who are taking inhaled corticosteroids (ICSs). Research conducted reveals that asthma patients who are taking ICSs, concomitant therapy with long-acting beta-agonists does not affect asthma-related hospitalization or serious adverse events. Children were excluded from the study and there is a paucity of information on the safety of LABAs in children.


Related Articles

  • Long-acting beta2-agonists in asthma: not so SMART? Currie, Graeme P.; Lee, Daniel K. C.; Lipworth, Brian J. // Drug Safety;2006, Vol. 29 Issue 8, p647 

    Asthma is a worldwide chronic disorder that is characterised by airway inflammation and hyper-responsiveness, which results in intermittent airflow obstruction and subsequent perception of symptoms and exacerbations. Inhaled corticosteroids are a fundamental component in the prevention of the...

  • Long-Acting Beta2 Agonists as Steroid-Sparing Agents. Kripke, Clarissa // American Family Physician;6/1/2006, Vol. 73 Issue 11, p1935 

    The article reports on a study which added a long-acting beta2 agonist to allow the dosage of maintenance inhaled corticosteroids to be reduced while maintaining asthma control. Details of how the study was conducted are given. The effectiveness of the agonist in reducing the steroid dosage is...

  • Maintenance plus as needed budesonide plus formoterol was better than fixed dose for severe exacerbations in asthma: Commentary. Rees, P. John // Evidence Based Medicine;Aug2005, Vol. 10 Issue 4, p116 

    Focuses on the control of asthma by inhaled long acting beta agonists and corticosteroids. Effectiveness of the combination of fluticasone/salmeterol and budesonide/formoterol; Dose response of corticosteroids and formoterol; Onset of bronchodilation.

  • The β2 receptor and airway hyper-responsiveness: are sensory nerves involved? Page, Clive // Thorax;Sep2009, Vol. 64 Issue 9, p2 

    The article discusses the effect of β2 receptor to the health condition of asthmatic patients. It indicates when β2 agonist drugs are used during monotherapy, it triggers bronchial hyper-responsiveness (BHR) and results to an increase in the allergen-induced early and late asthmatic...

  • Safety of Long-Acting Beta Agonists in Adults with Asthma. SAGUIL, AARON; GARCIA, DAVID // American Family Physician;10/1/2014, Vol. 90 Issue 7, p453 

    The article examines the impact of long-acting beta agonists (LABAs), with or without inhaled corticosteroids as treatment of adult asthma. It states the association of LABA monotherapy with an increase in nonfatal serious adverse events and asthma-related mortality. It also emphasizes that the...

  • Review: Long-acting β-agonists do not increase risk for asthma-related hospitalization in patients taking inhaled corticosteroids. Shafazand, Shirin // Einstein (16794508);Apr2010, Vol. 8 Issue 2, p75 

    The article focuses on the safety of using long-acting beta-agonists (LABA) with inhaled corticosteroids (ICS) for asthmatic patients in the U.S. A trial reveals that the use of LABA with ICS does not affect asthma-related hospitalization or serious adverse events for asthmatic patients....

  • Benefit-Risk Assessment of Long-Acting β2-Agonists in Asthma. Jackson, Catherine M.; Lipworth, Brian // Drug Safety;2004, Vol. 27 Issue 4, p243 

    The use of a regular long-acting β2-adrenoceptor agonists β2-agonists; LABA) is now established in asthma guidelines as the preferred option for second-line controller therapy in addition to inhaled corticosteroids. This has been driven by data showing beneficial effects of LABAs on...

  • Budesonide/Formoterol: A Viewpoint by Paul W. Jones. Jones, Paul W. // Drugs;2004, Vol. 64 Issue 4, p444 

    Budesonide/formoterol is a fixed-dose combination of the corticosteroid budesonide and formoterol, a long-acting J32-agonist, inhaled as a dry powder. Current guidelines for chronic obstructive pulmonary disease (COPD) recommend a long-acting p2-agonist for patients whose symptoms are not...

  • Budesonide/Formoterol: A Viewpoint by Michael Roth1,2. Michael Roth, Paul W. // Drugs;2004, Vol. 64 Issue 4, p443 

    This article presents views of the author on formoterol. Corticosteroids combined with long-acting J32-agonists, for example budesonide/formoterol, have been suggested for the treatment of inflammatory lung diseases, including asthma and chronic obstructive pulmonary disease (COPD). The...


Read the Article


Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics